Physician profile
Garrett Barton
NPI 1518349158
$3,214.31
in general payments reported to CMS, 2019-2025
31 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $755 · 2021: $648 · 2022: $32.53 · 2023: $135 · 2024: $435 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $482.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $476.62 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Amgen INC. | $344.77 | 2019-2021 | |
| Lilly USA, LLC | $333.29 | 2020-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $229.08 | 2021-2025 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.17 | 2019-2024 | Jardiance |
| Pfizer INC. | $196.70 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $103.03 | 2019-2024 | Belsomra, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $78.90 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $71.83 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $63.25 | 2019-2021 | |
| Allergan, INC. | $62.47 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.87 | 2019-2024 | Xifaxan |
| Eisai INC. | $53.44 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.15 | 2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $44.24 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $39.47 | 2021 | |
| Glaxosmithkline, LLC. | $29.97 | 2020-2025 | Trelegy Ellipta |
| Abbott Laboratories | $24.97 | 2019-2020 | |
| Genentech USA, INC. | $18.88 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.52 | 2025 | Rexulti |
| Amarin Pharma, INC. | $14.49 | 2019 | |
| Exact Sciences Corporation | $13.21 | 2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $13.19 | 2024 | Qelbree |
| Ironwood Pharmaceuticals, INC | $12.52 | 2019 | |
| Esperion Therapeutics, INC. | $12.24 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.08 | 2021 | |
| Currax Pharmaceuticals LLC | $11.80 | 2020 | |
| Hikma Pharmaceuticals USA | $11.29 | 2020 | |
| Fidia Pharma USA INC. | $9.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.